Financial Reports Latest Updates Industry Maps Economic Calendar

Protagonist Therapeutics, Inc (PTGX) Annual Reports

Q: Where can I read Protagonist Therapeutics, Inc (PTGX) annual reports?

Every year on this page links straight to the full text on SEC EDGAR. US annual reports are web pages (HTML) rather than PDFs, so you can read and search them in the browser. 3 filings are currently indexed.

Q: What is the difference between a 10-K and a 20-F?

A 10-K is the annual report of a US domestic issuer; a 20-F is filed by foreign private issuers (Taiwanese companies with US ADRs, such as TSMC, file 20-F). A 40-F applies to Canadian issuers under the MJDS.

Protagonist Therapeutics, Inc is listed on Nasdaq, classified by the SEC under Pharmaceutical Preparations (SIC 2834). This page indexes 3 annual reports, each linking to the full text on the SEC's EDGAR system.

Company profile

Exchange： Nasdaq
Fiscal year end： 12/31
SEC CIK： 1377121 →

Website：Official site ↗

Financial Highlights

FY2026 Q2 (quarterly, ended 2026-06-30)
	Current	Prior year	YoY
Revenue	$213.5M	$5.5M	+3749.2%
Operating income	$158.8M	$-42.0M	+477.6%
Net income	$162.8M	$-34.8M	+568.3%
EPS (diluted)	$2.29	$-0.55	+516.4%

Source: SEC EDGAR (XBRL company facts)

Financial history

Revenue & profit

Quarterly · In mn (USD)

Revenue 213 mn Net income 163 mn

Show table：Income statement

Item	2014Q4	2015Q1	2015Q2	2015Q3	2015Q4	2016Q1	2016Q2	2016Q3	2016Q4	2017Q1	2017Q2	2017Q3	2017Q4	2018Q1	2018Q2	2018Q3	2018Q4	2019Q1	2019Q2	2019Q3	2019Q4	2020Q1	2020Q2	2020Q3	2020Q4	2021Q1	2021Q2	2021Q3	2021Q4	2022Q1	2022Q2	2022Q3	2022Q4	2023Q1	2023Q2	2023Q3	2023Q4	2024Q1	2024Q2	2024Q3	2024Q4	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1	2026Q2
Revenue	—	—	—	—	—	—	—	0	—	—	—	8.78	11.3	10.8	11.7	6.12	2.35	1.56	—	4.14	2.72	—	—	13.1	5.65	6.19	2.27	10.3	8.62	25.7	0.86	0	0	0	0	0	60.0	255	4.17	4.68	171	28.3	5.55	4.71	7.44	56.4	213
Operating income	-9.32	-2.69	-3.08	-4.02	-5.00	-7.04	-7.09	-7.14	-11.4	-14.3	-15.1	-4.98	-3.51	-8.23	-9.24	-9.39	-15.4	-14.7	-31.4	-17.2	-17.3	-19.7	-18.2	-7.77	-18.8	-24.0	-30.9	-33.9	-37.0	-21.1	-41.4	-32.3	-36.5	-36.0	-42.4	-38.3	23.1	206	-38.8	-41.5	127	-19.3	-42.0	-46.4	-50.4	-3.65	159
Net income	-11.1	-2.70	-3.22	-3.45	-5.49	-11.8	-7.10	-7.08	-11.3	-14.1	-15.0	-4.82	-3.05	-7.66	-8.66	-8.73	-13.9	-14.1	-29.2	-16.4	-17.5	-20.1	-19.4	-7.76	-18.9	-24.0	-30.8	-33.8	-36.9	-20.9	-41.0	-31.2	-34.2	-33.7	-38.5	-34.1	27.3	207	-30.6	-33.2	132	-11.7	-34.8	-39.3	-44.4	3.78	163

Balance sheet

Quarterly · In mn (USD)

Total assets 886 mn Total liabilities 44.0 mn

Equity = assets − liabilities. Balance-sheet figures are period-end balances, not cumulative.

Show table：Balance sheet

Item	2014Q4	2015Q1	2015Q2	2015Q3	2015Q4	2016Q1	2016Q2	2016Q3	2016Q4	2017Q1	2017Q2	2017Q3	2017Q4	2018Q1	2018Q2	2018Q3	2018Q4	2019Q1	2019Q2	2019Q3	2019Q4	2020Q1	2020Q2	2020Q3	2020Q4	2021Q1	2021Q2	2021Q3	2021Q4	2022Q1	2022Q2	2022Q3	2022Q4	2023Q1	2023Q2	2023Q3	2023Q4	2024Q1	2024Q2	2024Q3	2024Q4	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1	2026Q2
Current assets	—	—	—	—	14.2	—	22.4	102	83.2	67.5	69.1	97.7	151	142	136	148	138	123	137	144	145	126	217	204	316	286	372	328	341	342	304	277	243	236	317	325	356	628	571	477	592	606	603	586	578	613	807
Total assets	—	—	—	—	14.8	—	24.5	103	94.0	82.7	70.5	110	164	149	137	149	139	132	148	155	155	135	225	217	324	298	404	373	348	348	311	282	248	240	320	330	358	629	615	604	745	742	718	702	668	697	886
Current liabilities	—	—	—	—	3.13	—	4.11	5.35	6.44	7.78	9.37	52.3	42.6	33.9	29.0	24.1	26.2	24.5	33.3	30.8	35.4	36.4	35.4	38.6	40.2	34.5	43.0	39.2	44.0	43.5	40.1	36.8	31.2	23.2	26.4	27.9	21.3	39.9	41.6	44.6	47.4	35.1	35.5	44.9	45.4	34.5	37.2
Total liabilities	—	—	—	—	5.25	—	4.11	5.35	6.44	—	9.45	52.6	43.1	34.6	29.8	24.9	27.0	31.4	63.8	59.3	75.0	72.2	57.5	47.7	44.9	38.7	46.8	43.5	47.7	46.5	42.5	38.6	32.3	23.7	26.4	27.9	21.3	68.8	73.3	71.9	69.4	53.1	50.0	56.3	53.5	42.0	44.0
Equity	-12.6	—	—	—	-27.4	—	-46.2	97.5	87.6	74.9	61.0	57.8	121	115	108	124	113	101	84.3	95.4	80.0	62.7	167	170	280	259	357	330	300	302	268	244	216	216	294	302	337	560	541	532	675	689	668	645	615	655	842

Cash flow

Quarterly · In mn (USD)

Operating 219 mn Investing -2.43 mn Financing 9.74 mn

Positive = cash in, negative = cash out.

Show table：Cash flow statement

Item	2014Q4	2015Q1	2015Q2	2015Q3	2015Q4	2016Q1	2016Q2	2016Q3	2016Q4	2017Q1	2017Q2	2017Q3	2017Q4	2018Q1	2018Q2	2018Q3	2018Q4	2019Q1	2019Q2	2019Q3	2019Q4	2020Q1	2020Q2	2020Q3	2020Q4	2021Q1	2021Q2	2021Q3	2021Q4	2022Q1	2022Q2	2022Q3	2022Q4	2023Q1	2023Q2	2023Q3	2023Q4	2024Q1	2024Q2	2024Q3	2024Q4	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1	2026Q2
Operating	-7.74	—	-5.88	-3.77	-4.74	-5.24	-8.07	-6.98	-9.68	-10.4	-12.3	40.7	-14.2	-15.1	-15.4	-9.28	-10.1	-16.7	3.67	-14.3	-14.3	-15.8	-21.5	-16.3	-18.9	-28.8	-23.7	-28.5	-26.9	-37.7	-13.6	-25.2	-31.6	-34.4	-26.2	-26.6	17.0	-27.4	269	-27.9	-29.2	125	-28.8	-1.94	-37.0	-48.9	219
Investing	-0.3	—	-0.07	-0.11	-8.09	7.15	-6.03	3.88	-64.3	-1.25	13.1	-0.77	4.75	-21.8	9.59	9.92	4.55	4.11	-13.2	-32.0	-12.6	42.7	-5.17	-54.1	-74.4	-6.79	7.77	-44.7	27.9	-4.48	34.7	57.3	3.94	9.83	25.8	-13.6	-61.3	6.07	-88.1	-209	-8.72	-94.4	54.8	-58.5	48.8	90.9	-2.43
Financing	9.00	—	0.06	17.4	0	22.6	-0.75	85.3	-0.85	0.37	0.09	0.03	65.1	0.53	0.07	23.0	0.48	0.39	10.6	25.2	9.78	0.4	113	7.67	127	0.98	125	1.38	2.17	16.9	0.68	0.68	0.55	26.5	108	35.3	0.53	7.20	2.57	12.1	4.03	11.4	2.93	5.66	2.84	23.4	9.74
Cash at period end	9.32	—	3.40	16.7	4.06	28.6	13.8	96.0	21.1	9.52	10.4	50.4	106	69.6	63.9	87.4	82.2	70.1	71.1	50.2	33.0	60.2	146	83.6	117	83.0	192	121	124	98.5	120	153	126	128	235	231	187	173	356	131	97.3	140	169	114	128	194	420

Profitability

Quarterly · %

Operating margin 74.4% Net margin 76.3%

Gross, operating and net margin = the respective profit ÷ revenue.

Show table：Profitability

Item	2014Q4	2015Q1	2015Q2	2015Q3	2015Q4	2016Q1	2016Q2	2016Q3	2016Q4	2017Q1	2017Q2	2017Q3	2017Q4	2018Q1	2018Q2	2018Q3	2018Q4	2019Q1	2019Q2	2019Q3	2019Q4	2020Q1	2020Q2	2020Q3	2020Q4	2021Q1	2021Q2	2021Q3	2021Q4	2022Q1	2022Q2	2022Q3	2022Q4	2023Q1	2023Q2	2023Q3	2023Q4	2024Q1	2024Q2	2024Q3	2024Q4	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1	2026Q2
Operating margin	—	—	—	—	—	—	—	—	—	—	—	-56.7%	-31.1%	-76.3%	-79.1%	-153.5%	-655.0%	-939.0%	—	-414.6%	-636.2%	—	—	-59.3%	-333.3%	-388.1%	-1363.4%	-329.8%	-429.6%	-82.1%	-4824.6%	—	—	—	—	—	38.4%	80.9%	-931.0%	-886.7%	74.3%	-68.2%	-758.0%	-985.2%	-677.1%	-6.5%	74.4%
Net margin	—	—	—	—	—	—	—	—	—	—	—	-55.0%	-27.1%	-71.1%	-74.2%	-142.8%	-589.3%	-904.0%	—	-396.3%	-643.7%	—	—	-59.2%	-334.3%	-387.8%	-1361.7%	-328.6%	-428.3%	-81.4%	-4777.3%	—	—	—	—	—	45.6%	81.3%	-734.7%	-710.4%	77.2%	-41.1%	-627.0%	-834.9%	-596.8%	6.7%	76.3%

Returns & leverage

Quarterly · %

ROE 11.0% ROA 10.3% Debt ratio 5.0%

ROE / ROA = trailing four-quarter net income ÷ average equity / total assets (annual mode: the year’s net income ÷ average of opening and closing). Not computed when the denominator is zero or negative.

Show table：Returns & leverage

Item	2014Q4	2015Q1	2015Q2	2015Q3	2015Q4	2016Q1	2016Q2	2016Q3	2016Q4	2017Q1	2017Q2	2017Q3	2017Q4	2018Q1	2018Q2	2018Q3	2018Q4	2019Q1	2019Q2	2019Q3	2019Q4	2020Q1	2020Q2	2020Q3	2020Q4	2021Q1	2021Q2	2021Q3	2021Q4	2022Q1	2022Q2	2022Q3	2022Q4	2023Q1	2023Q2	2023Q3	2023Q4	2024Q1	2024Q2	2024Q3	2024Q4	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1	2026Q2
ROE	—	—	—	—	—	—	—	-32.2%	-123.6%	-52.8%	-639.6%	-58.1%	-35.5%	-32.2%	-28.7%	-30.9%	-33.4%	-42.1%	-68.6%	-67.1%	-80.2%	-101.7%	-58.3%	-48.9%	-36.8%	-43.5%	-31.1%	-43.1%	-43.3%	-43.7%	-42.4%	-45.4%	-49.4%	-54.1%	-49.0%	-51.5%	-28.6%	41.8%	40.7%	41.0%	54.4%	9.0%	8.6%	7.8%	-20.2%	-17.1%	11.0%
ROA	—	—	—	—	-100.1%	—	-113.3%	-30.6%	-68.3%	-47.8%	-99.8%	-42.4%	-28.7%	-26.3%	-23.3%	-21.7%	-25.7%	-32.2%	-46.1%	-48.5%	-52.4%	-62.3%	-39.4%	-34.8%	-27.6%	-32.4%	-25.9%	-36.4%	-37.4%	-37.9%	-37.1%	-39.7%	-42.8%	-47.7%	-43.6%	-45.9%	-26.1%	37.3%	36.4%	36.6%	49.9%	8.2%	7.8%	7.0%	-18.4%	-15.9%	10.3%
Debt ratio	—	—	—	—	35.4%	—	16.8%	5.2%	6.8%	—	13.4%	47.6%	26.3%	23.2%	21.7%	16.7%	19.3%	23.8%	43.1%	38.3%	48.4%	53.5%	25.6%	22.0%	13.8%	13.0%	11.6%	11.7%	13.7%	13.4%	13.7%	13.7%	13.0%	9.9%	8.2%	8.4%	5.9%	10.9%	11.9%	11.9%	9.3%	7.2%	7.0%	8.0%	8.0%	6.0%	5.0%

EPS

Quarterly · US$

EPS US$2.29

Show table：EPS

Item	2014Q4	2015Q1	2015Q2	2015Q3	2015Q4	2016Q1	2016Q2	2016Q3	2016Q4	2017Q1	2017Q2	2017Q3	2017Q4	2018Q1	2018Q2	2018Q3	2018Q4	2019Q1	2019Q2	2019Q3	2019Q4	2020Q1	2020Q2	2020Q3	2020Q4	2021Q1	2021Q2	2021Q3	2021Q4	2022Q1	2022Q2	2022Q3	2022Q4	2023Q1	2023Q2	2023Q3	2023Q4	2024Q1	2024Q2	2024Q3	2024Q4	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1	2026Q2
EPS（US$）	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	-1.92	-0.54	-0.69	-0.70	-0.77	-0.43	-0.84	-0.64	-0.70	-0.67	-0.68	-0.58	0.52	3.26	-0.50	-0.54	2.01	-0.19	-0.55	-0.62	-0.70	0.05	2.29

Revenue & profit

Year-to-date · In mn (USD)

Revenue 270 mn Net income 167 mn

Year-to-date = summed from the first quarter of the fiscal year; balance-sheet items are period-end balances.

Balance sheet

Year-to-date · In mn (USD)

Total assets 886 mn Total liabilities 44.0 mn

Equity = assets − liabilities. Balance-sheet figures are period-end balances, not cumulative.

Cash flow

Year-to-date · In mn (USD)

Operating 170 mn Investing 88.5 mn Financing 33.1 mn

Positive = cash in, negative = cash out.

Profitability

Year-to-date · %

Operating margin 57.5% Net margin 61.8%

Gross, operating and net margin = the respective profit ÷ revenue.

Returns & leverage

Year-to-date · %

ROE 11.0% ROA 10.3% Debt ratio 5.0%

EPS

Year-to-date · US$

EPS US$2.34

Revenue & profit

Annual · In mn (USD)

Revenue 46.0 mn Net income -130 mn

Annual = sum of four quarters of a complete fiscal year (incomplete years are omitted); balance-sheet items are year-end balances.

Show table：Income statement

Item	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Revenue	—	—	—	30.9	—	—	27.4	26.6	60.0	434	46.0
Operating income	-14.8	-32.7	-37.9	-42.3	-80.5	-64.5	-126	-131	-93.7	253	-158
Net income	-14.9	-37.2	-37.0	-38.9	-77.2	-66.2	-126	-127	-79.0	275	-130

Balance sheet

Annual · In mn (USD)

Total assets 668 mn Total liabilities 53.5 mn

Equity = assets − liabilities. Balance-sheet figures are period-end balances, not cumulative.

Show table：Balance sheet

Item	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Current assets	14.2	83.2	151	138	145	316	341	243	356	592	578
Total assets	14.8	94.0	164	139	155	324	348	248	358	745	668
Current liabilities	3.13	6.44	42.6	26.2	35.4	40.2	44.0	31.2	21.3	47.4	45.4
Total liabilities	5.25	6.44	43.1	27.0	75.0	44.9	47.7	32.3	21.3	69.4	53.5
Equity	-27.4	87.6	121	113	80.0	280	300	216	337	675	615

Cash flow

Annual · In mn (USD)

Operating 57.7 mn Investing -49.3 mn Financing 22.9 mn

Positive = cash in, negative = cash out.

Show table：Cash flow statement

Item	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Operating	—	-30.0	3.87	-50.0	-41.5	-72.5	-108	-108	-70.2	184	57.7
Investing	—	-59.3	15.8	2.21	-53.7	-91.0	-15.9	91.5	-39.3	-299	-49.3
Financing	—	106	65.5	24.1	46.0	248	130	18.8	170	25.9	22.9
Cash at period end	4.06	21.1	106	82.2	33.0	117	124	126	187	97.3	128

Profitability

Annual · %

Operating margin -343.6% Net margin -282.8%

Gross, operating and net margin = the respective profit ÷ revenue.

Show table：Profitability

Item	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Operating margin	—	—	—	-136.7%	—	—	-460.0%	-494.2%	-156.1%	58.2%	-343.6%
Net margin	—	—	—	-125.9%	—	—	-458.9%	-479.3%	-131.6%	63.3%	-282.8%

Returns & leverage

Annual · %

ROE -20.2% ROA -18.4% Debt ratio 8.0%

Show table：Returns & leverage

Item	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
ROE	—	-123.6%	-35.5%	-33.4%	-80.2%	-36.8%	-43.3%	-49.4%	-28.6%	54.4%	-20.2%
ROA	-100.1%	-68.3%	-28.7%	-25.7%	-52.4%	-27.6%	-37.4%	-42.8%	-26.1%	49.9%	-18.4%
Debt ratio	35.4%	6.8%	26.3%	19.3%	48.4%	13.8%	13.7%	13.0%	5.9%	9.3%	8.0%

EPS

Annual · US$

EPS US$-2.06

Show table：EPS

Item	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
EPS（US$）	—	—	—	—	—	—	-2.70	-2.61	-1.41	4.23	-2.06

Source: SEC EDGAR (XBRL company facts)

Annual reports by year

	10-K
2025	Open full text →
2024	Open full text →
2023	Open full text →

10-K: annual report of a US domestic issuer. Filings are the original documents hosted on SEC EDGAR — this site neither mirrors nor edits them.

FAQ

Where can I read Protagonist Therapeutics, Inc (PTGX) annual reports?

Every year in the table above links straight to the full text on SEC EDGAR. US annual reports are web pages (HTML) rather than PDFs, so you can read and search them in the browser without downloading anything. 3 filings are currently indexed.

What is the difference between a 10-K and a 20-F?

A 10-K is the annual report of a US domestic issuer, with sections fixed by law: Item 1 Business, Item 1A Risk Factors, Item 7 Management's Discussion and Analysis. A 20-F is filed by foreign private issuers — Taiwanese companies with US ADRs, such as TSMC, file 20-F rather than 10-K. A 40-F applies to Canadian issuers under the MJDS.

Are earnings call materials available here?

No. Earnings calls are not SEC filings, so US pages on this site cover annual reports only. Taiwan has a mandatory investor-conference disclosure regime, and those materials are indexed under Annual Reports.

Source: US Securities and Exchange Commission (SEC) EDGAR. This site indexes public filings and links to them; it hosts no copies, offers no investment advice, and makes no warranty as to timeliness or completeness.
Back to US annual reports, or see the supply-chain maps.